Lupin Launches World's First Triple-Combination Inhaler for COPD in India
Lupin Limited has launched Formoflo-G MDI, the world's first fixed-dose triple combination metered-dose inhaler for managing moderate to severe chronic obstructive pulmonary disease (COPD) in India. Approved by the Drug Controller General of India, the inhaler combines glycopyrronium bromide, formoterol fumarate, and fluticasone propionate in a twice-daily dose. Lupin, ranked second in India's respiratory therapy segment, aims to expand treatment options for over 55 million COPD patients in the country with this new product.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (75/100). Lens Score 39/100.
Outlets measured: businessstandard, freepressjournal. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (75–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
freepressjournal broke this story on 6 Oct, 04:41 am. Other outlets followed.